Sony Corporation (NYSE:SNE) [Trend Analysis] moved up reacts as active mover, shares a gain 0.07% to trade at $28.74 and the percentage gap between open changing to regular change was -0.52%. Japanese consumer electronics giant Sony Corp. (SNE) declared that it has sold more than 6.2 million units of the PlayStation 4 or PS4 video game console worldwide during the 2016 holiday season.
The holiday season sales figures are based on retail sales data collected between November 20, 2016 and January 1, 2017, according to the company. PS4 has now cumulatively sold through more than 53.4 million units globally as of January 1, 2017 since its launch in 2013.
The firm’s current ratio calculated as 0.80 for the most recent quarter. The firm past twelve months price to sales ratio was 0.55 and price to cash ratio remained 2.93. As far as the returns are concern, the return on equity was recorded as 2.30% and return on investment was 5.80% while its return on asset stayed at 0.30%. The firm has total debt to equity ratio measured as 0.46.
Prima Biomed Ltd. (NASDAQ:PBMD) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.40% to close at $2.52 with the total traded volume of 2342 shares. Prima BioMed Ltd (NASDAQ:PBMD) declared that it has entered into a new collaboration contract with Japan’s CYTLIMIC, a recent spin off from NEC Corporation (NEC), to test a cancer peptide vaccine in combination with IMP321.
Prima’s Chief Medical Officer, Dr Frédéric Triebel, said: “When IMP321 is used as an adjuvant to a cancer vaccine to boost tumour-specific CD8 T cells, it is used at a very low dose to get a local effect at the vaccine injection site. The use of IMP321 as an adjuvant to a vaccine is therefore different from Prima’s other combination approaches where higher doses are used to boost Antigen Presenting Cells (APCs) in the whole body. It is very encouraging that CYTLIMIC has committed further resources to this exciting research, based on several positive published studies using IMP321 as an adjuvant to cancer vaccines.”
CYTLIMIC’s President and Chief Executive Officer, Dr Shun Doi, said: “I am pleased with the progress to enter into this collaboration with Prima BioMed, which follows the successful research collaboration among NEC Corporation, Yamaguchi University and Prima BioMed, to realize an innovative peptide vaccine for cancer immunotherapy.” Its price to sales ratio ended at 135.13. PBMD attains analyst recommendation of 1.70 with week’s performance of 7.73%.